<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055653</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000270487</org_study_id>
    <secondary_id>RPCI-DS-00-22</secondary_id>
    <nct_id>NCT00055653</nct_id>
  </id_info>
  <brief_title>Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders</brief_title>
  <official_title>Unrelated Umbilical Cord Blood As An Alternate Source Of Stem Cells Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Umbilical cord blood transplantation may be able to replace immune cells that were&#xD;
      destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of allogeneic umbilical cord blood&#xD;
      transplantation in treating patients who have leukemia, lymphoma, or nonmalignant hematologic&#xD;
      disorders.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine 180-day survival in patients with malignant or nonmalignant hematologic&#xD;
           diseases treated with allogeneic umbilical cord blood transplantation. (Severe aplastic&#xD;
           anemia, Fanconi anemia, and marrow failure syndromes strata are closed to accrual; adult&#xD;
           [over 18 years of age] patient stratum is closed to accrual.)&#xD;
&#xD;
        -  Determine disease-free and long-term survival in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of neutrophil engraftment, primary and secondary graft failure,&#xD;
           platelet engraftment, and red blood cell engraftment in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the incidence and severity of acute and chronic graft-versus-host disease in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of complications, including infection, veno-occlusive disease,&#xD;
           and interstitial pneumonitis, in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the incidence of relapse, other malignancies, lymphoproliferative disorders,&#xD;
           and posttransplantation myelodysplasia in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the immune reconstitution in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are grouped according to the following strata:&#xD;
&#xD;
        -  Stratum I: Malignant disease, 5/6 or 6/6 HLA match, age 18 and under&#xD;
&#xD;
        -  Stratum II: Malignant disease, 4/6 HLA match, age 18 and under&#xD;
&#xD;
        -  Stratum III: Malignant disease, 3/6 HLA match, age 18 and under&#xD;
&#xD;
        -  Stratum IV: Malignant disease, 2/6 or 1/6 HLA match, age 18 and under&#xD;
&#xD;
        -  Stratum V (closed to accrual): Severe aplastic anemia, Fanconi anemia, or other marrow&#xD;
           failure syndrome&#xD;
&#xD;
        -  Stratum VI: Inborn errors of metabolism/storage diseases and other nonmalignant diseases&#xD;
           not included in stratum V&#xD;
&#xD;
        -  Stratum VII: Malignant disease receiving alternative conditioning regimen comprising&#xD;
           busulfan and melphalan&#xD;
&#xD;
        -  Stratum VIII (closed to accrual): Adult patients (over age 18)&#xD;
&#xD;
        -  Conditioning therapy: Patients are assigned to 1 of 5 groups according to diagnosis.&#xD;
&#xD;
             -  Group I (malignant disease or severe aplastic anemia [severe aplastic anemia closed&#xD;
                to accrual]): Patients undergo total body irradiation (TBI) once or twice daily on&#xD;
                days -8 to -4. Patients then receive cyclophosphamide IV on days -3 and -2,&#xD;
                methylprednisolone IV on days -3 to 0, and antithymocyte globulin (ATG) IV once or&#xD;
                twice daily on days -3 to -1.&#xD;
&#xD;
             -  Group II (Fanconi anemia [closed to accrual]): Patients undergo TBI on day -6, and&#xD;
                then receive cyclophosphamide IV and fludarabine IV on days -5 to -2, and&#xD;
                methylprednisolone IV and ATG IV on days -5 to -1.&#xD;
&#xD;
             -  Group III (inborn errors of metabolism/storage disease): Patients receive oral&#xD;
                busulfan 4 times daily on days -9 to -6, cyclophosphamide as in group II, and&#xD;
                methylprednisolone and ATG as in group I.&#xD;
&#xD;
             -  Group IV (other nonmalignant diseases): Patients receive conditioning therapy as in&#xD;
                group III. Patients with familial erythrophagocytic lymphohistiocytosis or&#xD;
                Langerhans cell histiocytosis also receive etoposide on days -5 to -3.&#xD;
&#xD;
             -  Group V (non-TBI regimen for leukemia patients under 2 years of age): Patients&#xD;
                receive oral busulfan 4 times daily on days -8 to -5, melphalan IV on days -4 to&#xD;
                -2, and methylprednisolone and ATG as in group I.&#xD;
&#xD;
        -  Allogeneic umbilical cord blood transplantation: All patients undergo umbilical cord&#xD;
           blood transplantation on day 0. Beginning on day 0 or 1, patients receive filgrastim&#xD;
           (G-CSF) IV or subcutaneously daily until blood counts recover.&#xD;
&#xD;
        -  Graft-versus-host disease prophylaxis: Patients receive cyclosporine (IV or oral)&#xD;
           beginning between days -3 and -1 and continuing for 1 year after transplantation and&#xD;
           methylprednisolone twice daily beginning on day 1 and continuing until blood counts&#xD;
           recover.&#xD;
&#xD;
      Patients are followed weekly for 14 weeks, at 100 days, and at 4, 5, 6, 9, 12, 18, 24, and 36&#xD;
      months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 360 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">September 2005</completion_date>
  <primary_completion_date type="Actual">September 2003</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic-Myeloproliferative Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of 1 of the following hematologic malignancies:&#xD;
&#xD;
               -  Acute myeloid leukemia (AML)*&#xD;
&#xD;
                    -  With or without history of myelodysplastic syndromes (MDS)&#xD;
&#xD;
                    -  Patients in first complete remission (CR) (no greater than 5% blasts in&#xD;
                       marrow) with translocations t(8;21) and inv(16) are allowed provided they&#xD;
                       failed first-line induction therapy&#xD;
&#xD;
                    -  Patients in first CR (no greater than 5% blasts in marrow) with&#xD;
                       translocations t(15;17) are allowed provided at least 1 of the following is&#xD;
                       true:&#xD;
&#xD;
                         -  Failed first-line induction therapy&#xD;
&#xD;
                         -  Molecular evidence of persistent disease&#xD;
&#xD;
                    -  No patients in first CR and with Down syndrome&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL)*, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Not in first CR (no greater than 5% blasts in marrow)&#xD;
&#xD;
                    -  In first CR and high risk as defined by 1 of the following:&#xD;
&#xD;
                         -  Hypoploidy (no more than 44 chromosomes)&#xD;
&#xD;
                         -  Pseudodiploidy with translocations or molecular evidence of t(9;22),&#xD;
                            11q23, or t(8;14) (excluding B-ALL) or +MLL gene rearrangement&#xD;
&#xD;
                         -  One of the following elevated WBC levels:&#xD;
&#xD;
                              -  WBC greater than 100,000/mm^3 if 6 to 12 months of age&#xD;
&#xD;
                              -  WBC greater than 200,000/mm^3 if between 10 and 17 years of age&#xD;
&#xD;
                              -  WBC greater than 20,000/mm^3 if 18 years of age and over (adult&#xD;
                                 [over 18 years of age] patient stratum closed to accrual)&#xD;
&#xD;
                         -  Failed to achieve CR after 4 weeks of induction therapy&#xD;
&#xD;
                    -  B-ALL that is not in first CR or that meets at least 1 of the high-risk&#xD;
                       criteria specified above&#xD;
&#xD;
                         -  No translocation t(8;14)&#xD;
&#xD;
                         -  No blasts with surface immunoglobulins&#xD;
&#xD;
                         -  CD10 negative&#xD;
&#xD;
               -  Undifferentiated leukemia*&#xD;
&#xD;
               -  Infant leukemia*&#xD;
&#xD;
               -  Biphenotypic leukemia*&#xD;
&#xD;
               -  Chronic myelogenous leukemia, meeting 1 of the following criteria:&#xD;
&#xD;
                    -  Accelerated phase&#xD;
&#xD;
                    -  Chronic phase&#xD;
&#xD;
                         -  At least 1 year from diagnosis without an identified matched unrelated&#xD;
                            bone marrow donor AND unresponsive to or unable to tolerate interferon&#xD;
&#xD;
                    -  Blast crisis* (greater than 30% promyelocytes plus blasts in the marrow)&#xD;
&#xD;
               -  One of the following MDS:&#xD;
&#xD;
                    -  Refractory anemia&#xD;
&#xD;
                    -  Refractory anemia with ringed sideroblasts&#xD;
&#xD;
                    -  Refractory anemia with excess blasts (RAEB)&#xD;
&#xD;
                    -  RAEB in transformation&#xD;
&#xD;
                    -  Chronic myelomonocytic leukemia&#xD;
&#xD;
               -  Paroxysmal nocturnal hemoglobinuria&#xD;
&#xD;
               -  Hodgkin's or non-Hodgkin's lymphoma beyond first CR or failed primary induction&#xD;
                  therapy&#xD;
&#xD;
                    -  Tumor displays chemosensitivity (greater than 50% reduction in mass size&#xD;
                       after the most recent therapy) NOTE: *Patients in third or greater medullary&#xD;
                       relapse or refractory disease (other than primary induction failures) or&#xD;
                       blast crisis receive the study busulfan/melphalan conditioning regimen)&#xD;
&#xD;
        OR&#xD;
&#xD;
          -  Diagnosis of one of the following nonmalignant diseases :&#xD;
&#xD;
               -  Acquired severe aplastic anemia (stratum closed to accrual)&#xD;
&#xD;
                    -  Unresponsive to medical therapy with anti-thymocyte globulin and/or&#xD;
                       cyclosporine&#xD;
&#xD;
               -  Inborn errors of metabolism, including, but not limited to the following:&#xD;
&#xD;
                    -  Hurler's syndrome&#xD;
&#xD;
                    -  Adrenoleukodystrophy&#xD;
&#xD;
                    -  Maroteaux-Lamy syndrome&#xD;
&#xD;
                    -  Globoid cell leukodystrophy&#xD;
&#xD;
                    -  Metachromatic leukodystrophy&#xD;
&#xD;
                    -  Fucosidosis&#xD;
&#xD;
                    -  Mannosidosis&#xD;
&#xD;
               -  Fanconi anemia documented by increased chromosomal fragility assays and meeting 1&#xD;
                  of the following criteria (stratum closed to accrual):&#xD;
&#xD;
                    -  Severe pancytopenia&#xD;
&#xD;
                         -  Absolute neutrophil count less than 500/mm^3&#xD;
&#xD;
                         -  Platelet count less than 20,000/mm^3&#xD;
&#xD;
                         -  Hemoglobin less than 8 g/dL&#xD;
&#xD;
                    -  Morphologic evidence of MDS with clonal chromosomal abnormalities&#xD;
&#xD;
                    -  Leukemia transformation&#xD;
&#xD;
               -  Other marrow failure syndromes, including any of the following (stratum closed to&#xD;
                  accrual):&#xD;
&#xD;
                    -  Blackfan-Diamond syndrome that is unresponsive to medical therapy&#xD;
&#xD;
                    -  Kostmann's congenital agranulocytosis unresponsive to medical therapy&#xD;
&#xD;
                    -  Congenital amegakaryocytic thrombocytopenia&#xD;
&#xD;
                    -  Thrombocytopenia absent radius&#xD;
&#xD;
               -  Combined immune deficiencies including, but not limited to the following:&#xD;
&#xD;
                    -  Severe combined immunodeficiency (SCID)&#xD;
&#xD;
                    -  Wiskott-Aldrich syndrome&#xD;
&#xD;
                    -  Leukocyte adhesion defect&#xD;
&#xD;
                    -  Chediak-Higashi disease&#xD;
&#xD;
                    -  X-linked lymphoproliferative disease&#xD;
&#xD;
                    -  Adenosine deaminase deficiency&#xD;
&#xD;
                    -  Purine nucleoside phosphorylase deficiency&#xD;
&#xD;
                    -  X-linked SCID&#xD;
&#xD;
                    -  Common variable immune deficiency&#xD;
&#xD;
                    -  Nezeloff's syndrome&#xD;
&#xD;
                    -  Cartilage hair hypoplasia&#xD;
&#xD;
                    -  Reticular dysgenesis&#xD;
&#xD;
          -  No active CNS leukemia (cerebrospinal fluid with WBC greater than 5/mm^3 and malignant&#xD;
             cells on cytospin)&#xD;
&#xD;
          -  No SCID patients who do not require cytoreduction&#xD;
&#xD;
          -  No dyskeratosis congenita&#xD;
&#xD;
          -  No primary myelofibrosis&#xD;
&#xD;
          -  No grade 3 or greater myelofibrosis&#xD;
&#xD;
          -  Familial erythrophagocytic lymphohistiocytosis patients must not have any of the&#xD;
             following:&#xD;
&#xD;
               -  Abnormal brain MRI&#xD;
&#xD;
               -  Neurologic symptoms&#xD;
&#xD;
               -  Lymphocytes and monocytes greater than 7/mm^3 in the cerebrospinal fluid&#xD;
&#xD;
          -  No available 5/6 or 6/6 HLA-matched related donor&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  55 and under (over 18 closed to accrual)&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Karnofsky 70-100% OR&#xD;
&#xD;
          -  Lansky 50-100% (patients under 16 years old)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  SGOT less than 5 times upper limit of normal&#xD;
&#xD;
          -  Bilirubin less than 2.5 mg/dL&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal for age OR&#xD;
&#xD;
          -  Creatinine clearance or glomerular filtration rate greater than 50% of lower limit of&#xD;
             normal&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF greater than 40% at rest and must improve with exercise* OR&#xD;
&#xD;
          -  Shortening fraction greater than 26%* NOTE: *If symptomatic&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  DLCO greater than 45% of predicted* (corrected for hemoglobin)&#xD;
&#xD;
          -  FEV_1 and FEC greater than 45% of predicted (corrected for hemoglobin) OR&#xD;
&#xD;
          -  Room air oxygen saturation greater than 85%* NOTE: *If symptomatic&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No uncontrolled viral, bacterial, or fungal infection&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 12 months since prior allogeneic stem cell transplantation with&#xD;
             cytoreductive preparative therapy&#xD;
&#xD;
          -  More than 6 months since prior autologous stem cell transplantation&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Biologic therapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior enrollment on this study&#xD;
&#xD;
          -  No continuous life support (e.g., mechanical ventilation) within 1 year after study&#xD;
             transplantation (for patients with inborn errors of metabolism)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip L. McCarthy, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027-0700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Orange County</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center, University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-1278</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of New Orleans</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spectrum Health and DeVos Children's Hospital</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Glennon Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104-1095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James P. Wilmot Cancer Center at University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Comprehensive Cancer Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6310</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Dallas Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Medical Center of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>March 3, 2011</last_update_submitted>
  <last_update_submitted_qc>March 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Philip McCarthy</name_title>
    <organization>Roswell Park Cancer Institute</organization>
  </responsible_party>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with ringed sideroblasts</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>untreated childhood acute lymphoblastic leukemia</keyword>
  <keyword>untreated childhood acute myeloid leukemia and other myeloid malignancies</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

